Endometrial CancerTRENDNCT04783467
Time Restricted Eating (TRE) Among Endometrial Cancer Patients
A study testing Time Restricted Eating (TRE) Schedule in people with Endometrial Cancer, run by University of Utah at 1 site in United States.
Trial summary
The long-term goal of this study is to determine the efficacy of Time Restricted Eating (TRE) for improving metabolic health, preventing cardiometabolic comorbidities, and improving prognosis after endometrial cancer diagnosis. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Endometrial Cancer
- What is being tested?
- Time Restricted Eating (TRE) Schedule
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 1 siteUnited States
- Study dates
- 7 Oct 2021to Jun 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Females aged 18 years or older
- Diagnosed with endometrial cancer (any stage)
- Clinically overweight or obese (BMI >= 25 kg/m2)
- At least 3 months post-cancer surgery and/or treatment
- Weight stable for 3 months prior to beginning the study (<4kg weight loss/gain)
- Have a cell phone that is able to download a phone App and able to use phone during the day
Who cannot join
- Persons with special dietary requirements
- Unable to provide informed consent
- Unable to read, write, or fill in questionnaires in English
- Insulin dependent diabetes
- Night shift workers
- Persons not able to use cell phone during day (like for work)
Trial locations and contacts
1 site in 1 country.
United States1 site, 1 recruiting
- Recruiting
Huntsman Cancer Institute
Salt Lake City, Utah, 84112
Mary Playdon, PhD, MPH, 801-213-6264, mary.playdon@hci.utah.edu
About this study
Official title: Feasibility and Acceptability of Time Restricted Eating (TRE) Among Endometrial Cancer Patients: the TREND Study
The long-term goal of this study is to determine the efficacy of Time Restricted Eating (TRE) for improving metabolic health, preventing cardiometabolic comorbidities, and improving prognosis after endometrial cancer diagnosis. The primary objective of the protocol is to conduct a 16-week randomized dietary crossover study to evaluate the feasibility, fidelity and preliminary acceptability of TRE among endometrial cancer patients, and to provide proof of principle that TRE can improve metabolic health in this population.
Read the detailed description
Enrollment: The study team will aim to recruit 15 endometrial cancer patients seen at the Huntsman Cancer Hospital Clinics. Consent may be completed via phone/email or in-person with the study clinical coordinator.
Dietary Intervention: Participants who are consented into the study will participate in a 16-week randomized dietary crossover intervention. The dietary intervention includes 5 study visits, and features a baseline visit, 2-week run-in period, 4-week control diet schedule with prepared frozen meals provided to participants, 4-week washout period, and a 6-week, 8 to 10-hour Time Restricted Eating (TRE) protocol (meal provision with 8 to 10-hour eating and 14 to 16-hour fasting periods). Women will be randomized to either control or TRE, then crossover to the other condition. For the control schedule, women will receive frozen lunch and dinner meals and be provided with a standardized breakfast and snacks menu, and there are no restrictions on timing of eating. For the TRE schedule, women will receive prepared frozen lunch and dinner meals as per the control schedule, but will be asked to consume daily meals, snacks, and calorie-containing beverages within an 8 to 10-hour period that fits their schedule. Fasting period will ramp up during the first week (e.g., Days 1-3, 12-14 h per day, Days 4-6, 14-16 h per day, Days 7+, 16 h per day). Women will be asked to schedule the eating period at the same time each day.
Study Visits and Assessments: Women will attend in-person study visits at the Huntsman Cancer Institute Center for Health Outcomes and Population Equity (HOPE).
- Baseline Visit (Visit 1): The clinical coordinator will obtain consent from the participant. Once consented, women will complete questionnaires to capture information on clinical and demographic factors, and chronotype. Height will be measured using stadiometer, weight will be measured using calibrated scales, waist circumference with measuring tape and blood pressure (BP) using an electronic BP monitor. Participants may take home questionnaires, with mailer, to complete at home.
- 2-Week Run-In Period: The purpose of the run-in period is to record women's usual times of eating episodes and appetite while following their habitual diet. Appetite will be measured using the MyCircacianClock (mCC) phone app that has the capability to sample subjects' current behaviors and experiences in real time in their natural environment. Women will complete 3 x 24-hour dietary recalls on non-consecutive days (ASA-24) and a physical activity recall (ACT24 available online or phone app, or via telephone conference with the clinical coordinator). Sleep and activity will also be objectively measured for 7-days using an Actiwatch.
- Visit 2: Women will provide fasting blood and stool samples. Weight, waist circumference and blood pressure will be measured.
- Control OR TRE Schedules: The participants will be expected to follow their randomized schedule for meal timing. During these schedules, for both study groups, participants will record timing of eating episodes daily using the MyCircadianClock app, complete 3 x 24-hour recalls (ASA24), 1 x ACT24 activity recall, and 7-days of sleep/physical activity will be objectively measured via Actiwatch.
- Visit 3: Women will provide fasting blood and stool samples. Weight, waist circumference and blood pressure will be measured.
- 4-Week Washout Period: During the washout period, women can return to their usual lifestyle. Meals will not be provided during this time.
- Visit 4: Visit 4 will include a telephone call only to discuss the next study phase and schedule meal provision.
- Visit 5: Women will provide fasting blood and stool samples. Weight, waist circumference and blood pressure will be measured. An exit interview may occur in person or via phone/video conference to ask questions about how well the intervention was tolerated and allow participants to provide feedback.
- Follow-Up: Approximately 6-months after consent and roughly 10 weeks after the end of the dietary intervention, participants will be asked to complete a follow-up questionnaire.
- Conditions
- Endometrial Cancer
- Being tested
- Time Restricted Eating (TRE) Schedule
- Medical subject headings
- Endometrial Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Time Restricted Eating (TRE) ScheduleBehavioural
[See arm/group descriptions]
| Study group | Role | What they receive |
|---|---|---|
| Time Restricted Eating (TRE) Schedule | Experimental | For 6-weeks out of the 16-week randomized dietary crossover study, women will receive prepared frozen lunch and dinner meals as per the control schedule, but will be asked to consume daily meals, snacks, and calorie-containing beverages within an 8 to 10-hour period that fits their schedule. The meal plans will be individualized to meet weight maintenance energy requirements. Receives: Behavioral: Time Restricted Eating (TRE) Schedule |
| Control Schedule | No intervention | For 4 weeks out of the 16-week randomized dietary crossover study, women will receive frozen lunch and dinner meals, and a standardized breakfast and snacks menu. The meal plans will be individualized to meet weight maintenance energy requirements. There are no restrictions on timing of eating. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of Women Referred that are Consented
Feasibility of the TRE intervention will be measured be calculating the proportion (%) of women who were referred that were consented into the study. The study will be considered feasible of > 70% of participants are consented and retained.
Measured: From baseline to Visit 5 (Week 16)
Attrition as a Function of Time
Number of participants who withdraw throughout the course of the study.
Measured: From baseline to Visit 5 (Week 16)
Percent of Scheduled Assessments Completed
Feasibility of the TRE intervention will be assessed by calculating a percentage of scheduled biospecimen collection and questionnaires completed.
Measured: From baseline to Visit 5 (Week 16)
Number of TRE-Adherent Days per Week
Feasibility of the TRE intervention will be measured by calculating the number of TRE-adherent days per week. Participants will be considered adherent if they fasted between 14-16 hours per day during the TRE phase according to the MCC App mealtime log. The study will be considered feasible if women adhere to the TRE protocol on average 5 days per week.
Measured: From baseline to Visit 5 (Week 16)
Fidelity of Time Restricted Eating (TRE) Intervention
Fidelity will be evaluated as a percentage of protocol checklist items delivered as intended with a goal of 90%
Measured: From baseline to Visit 5 (Week 16)
Secondary outcomes (9)
Change in blood pressure assessed via electronic blood pressure monitor
Blood pressure will be taken using an electronic blood pressure monitor.
Measured: Baseline (Visit 1), Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Change in waist circumference assessed via measuring tape
Waist circumference will be measured using a measuring tape.
Measured: Baseline (Visit 1), Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Change in BMI assessed via height and weight
Participants' height and weight will be measured with stadiometer and electronic scales and used to calculate BMI.
Measured: Baseline (Visit 1), Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Change in fasting blood glucose assessed via blood draw
A small sample of blood will be taken from participants at designated study visits.
Measured: Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Change in HOMA-IR assessed via blood draw
A small sample of blood will be taken from participants at designated study visits.
Measured: Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Change in c-peptide assessed via blood draw
A small sample of blood will be taken from participants at designated study visits
Measured: Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Change in triglycerides assessed via blood draw
A small sample of blood will be taken from participants at designated study visits
Measured: Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Change in HDL-cholesterol assessed via blood draw
A small sample of blood will be taken from participants at designated study visits
Measured: Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Change in high sensitivity C-reactive protein assessed via blood draw
A small sample of blood will be taken from participants at designated study visits
Measured: Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Mar 2021
- Study start7 Oct 2021
- Primary completionJun 2024 (estimated)
- Study completionJun 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Endometrial CancerStudies of the same condition, open and under way.
- More trials run by University of UtahThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Utah
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mary Playdon, University of Utah
- Investigators
- Mary Playdon, PhD, MPH, Principal investigator, University of Utah
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04783467
- Sponsor's protocol ID
- IRB_00126714
- Acronym
- TREND
- Status last verified
- Nov 2023
- First submitted
- 18 Feb 2021
- Last updated
- 30 Nov 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Agnew H, Kitson S, Crosbie EJ. Interventions for weight reduction in obesity to improve survival in women with endometrial cancer. Cochrane Database Syst Rev. 2023 Mar 27;3(3):CD012513. doi: 10.1002/14651858.CD012513.pub3.
PubMed 36971688
Study at a glance
From the registry record, last updated by the sponsor on 30 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility and Acceptability of Time Restricted Eating (TRE) Among Endometrial Cancer Patients: the TREND Study
- ClinicalTrials.gov ID
- NCT04783467
- Acronym / sponsor ID
- TREND / IRB_00126714
- Conditions
- Endometrial Cancer
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- University of UtahUniversity, hospital or other
- Study start
- 7 Oct 2021 (actual)
- Primary completion
- Jun 2024 (estimated)
- Study completion
- Jun 2024 (estimated)
- First posted
- 5 Mar 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The long-term goal of this study is to determine the efficacy of Time Restricted Eating (TRE) for improving metabolic health, preventing cardiometabolic comorbidities, and improving prognosis after endometrial cancer diagnosis. The primary objective of the protocol is to conduct a 16-week randomized dietary crossover study to evaluate the feasibility, fidelity and preliminary acceptability of TRE among endometrial cancer patients, and to provide proof of principle that TRE can improve metabolic health in this population.
Detailed description
Enrollment: The study team will aim to recruit 15 endometrial cancer patients seen at the Huntsman Cancer Hospital Clinics. Consent may be completed via phone/email or in-person with the study clinical coordinator.
Dietary Intervention: Participants who are consented into the study will participate in a 16-week randomized dietary crossover intervention. The dietary intervention includes 5 study visits, and features a baseline visit, 2-week run-in period, 4-week control diet schedule with prepared frozen meals provided to participants, 4-week washout period, and a 6-week, 8 to 10-hour Time Restricted Eating (TRE) protocol (meal provision with 8 to 10-hour eating and 14 to 16-hour fasting periods). Women will be randomized to either control or TRE, then crossover to the other condition. For the control schedule, women will receive frozen lunch and dinner meals and be provided with a standardized breakfast and snacks menu, and there are no restrictions on timing of eating. For the TRE schedule, women will receive prepared frozen lunch and dinner meals as per the control schedule, but will be asked to consume daily meals, snacks, and calorie-containing beverages within an 8 to 10-hour period that fits their schedule. Fasting period will ramp up during the first week (e.g., Days 1-3, 12-14 h per day, Days 4-6, 14-16 h per day, Days 7+, 16 h per day). Women will be asked to schedule the eating period at the same time each day.
Study Visits and Assessments: Women will attend in-person study visits at the Huntsman Cancer Institute Center for Health Outcomes and Population Equity (HOPE).
- Baseline Visit (Visit 1): The clinical coordinator will obtain consent from the participant. Once consented, women will complete questionnaires to capture information on clinical and demographic factors, and chronotype. Height will be measured using stadiometer, weight will be measured using calibrated scales, waist circumference with measuring tape and blood pressure (BP) using an electronic BP monitor. Participants may take home questionnaires, with mailer, to complete at home.
- 2-Week Run-In Period: The purpose of the run-in period is to record women's usual times of eating episodes and appetite while following their habitual diet. Appetite will be measured using the MyCircacianClock (mCC) phone app that has the capability to sample subjects' current behaviors and experiences in real time in their natural environment. Women will complete 3 x 24-hour dietary recalls on non-consecutive days (ASA-24) and a physical activity recall (ACT24 available online or phone app, or via telephone conference with the clinical coordinator). Sleep and activity will also be objectively measured for 7-days using an Actiwatch.
- Visit 2: Women will provide fasting blood and stool samples. Weight, waist circumference and blood pressure will be measured.
- Control OR TRE Schedules: The participants will be expected to follow their randomized schedule for meal timing. During these schedules, for both study groups, participants will record timing of eating episodes daily using the MyCircadianClock app, complete 3 x 24-hour recalls (ASA24), 1 x ACT24 activity recall, and 7-days of sleep/physical activity will be objectively measured via Actiwatch.
- Visit 3: Women will provide fasting blood and stool samples. Weight, waist circumference and blood pressure will be measured.
- 4-Week Washout Period: During the washout period, women can return to their usual lifestyle. Meals will not be provided during this time.
- Visit 4: Visit 4 will include a telephone call only to discuss the next study phase and schedule meal provision.
- Visit 5: Women will provide fasting blood and stool samples. Weight, waist circumference and blood pressure will be measured. An exit interview may occur in person or via phone/video conference to ask questions about how well the intervention was tolerated and allow participants to provide feedback.
- Follow-Up: Approximately 6-months after consent and roughly 10 weeks after the end of the dietary intervention, participants will be asked to complete a follow-up questionnaire.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Time Restricted Eating (TRE) Schedule | Experimental | Behavioral: Time Restricted Eating (TRE) ScheduleFor 6-weeks out of the 16-week randomized dietary crossover study, women will receive prepared frozen lunch and dinner meals as per the control schedule, but will be asked to consume daily meals, snacks, and calorie-containing beverages within an 8 to 10-hour period that fits their schedule. The meal plans will be individualized to meet weight maintenance energy requirements. |
| Control Schedule | No intervention | –For 4 weeks out of the 16-week randomized dietary crossover study, women will receive frozen lunch and dinner meals, and a standardized breakfast and snacks menu. The meal plans will be individualized to meet weight maintenance energy requirements. There are no restrictions on timing of eating. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Females aged 18 years or older
- Diagnosed with endometrial cancer (any stage)
- Clinically overweight or obese (BMI >= 25 kg/m2)
- At least 3 months post-cancer surgery and/or treatment
- Weight stable for 3 months prior to beginning the study (<4kg weight loss/gain)
Key exclusion criteria (6 listed)
- Persons with special dietary requirements
- Unable to provide informed consent
- Unable to read, write, or fill in questionnaires in English
- Insulin dependent diabetes
- Night shift workers
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Time Restricted Eating (TRE) Schedule[See arm/group descriptions] | Behavioural | Time Restricted Eating (TRE) Schedule |
Primary outcome
Proportion of Women Referred that are Consented
Time frame: From baseline to Visit 5 (Week 16)
Feasibility of the TRE intervention will be measured be calculating the proportion (%) of women who were referred that were consented into the study. The study will be considered feasible of > 70% of participants are consented and retained.
Attrition as a Function of Time
Time frame: From baseline to Visit 5 (Week 16)
Number of participants who withdraw throughout the course of the study.
Percent of Scheduled Assessments Completed
Time frame: From baseline to Visit 5 (Week 16)
Feasibility of the TRE intervention will be assessed by calculating a percentage of scheduled biospecimen collection and questionnaires completed.
Number of TRE-Adherent Days per Week
Time frame: From baseline to Visit 5 (Week 16)
Feasibility of the TRE intervention will be measured by calculating the number of TRE-adherent days per week. Participants will be considered adherent if they fasted between 14-16 hours per day during the TRE phase according to the MCC App mealtime log. The study will be considered feasible if women adhere to the TRE protocol on average 5 days per week.
Fidelity of Time Restricted Eating (TRE) Intervention
Time frame: From baseline to Visit 5 (Week 16)
Fidelity will be evaluated as a percentage of protocol checklist items delivered as intended with a goal of 90%
9 secondary outcomes
Change in blood pressure assessed via electronic blood pressure monitor
Time frame: Baseline (Visit 1), Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Change in waist circumference assessed via measuring tape
Time frame: Baseline (Visit 1), Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Change in BMI assessed via height and weight
Time frame: Baseline (Visit 1), Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Change in fasting blood glucose assessed via blood draw
Time frame: Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Change in HOMA-IR assessed via blood draw
Time frame: Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Change in c-peptide assessed via blood draw
Time frame: Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Change in triglycerides assessed via blood draw
Time frame: Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Change in HDL-cholesterol assessed via blood draw
Time frame: Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Change in high sensitivity C-reactive protein assessed via blood draw
Time frame: Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Nov 2023.
- Derived from this study: PubMed 36971688Agnew H, Kitson S, Crosbie EJ. Interventions for weight reduction in obesity to improve survival in women with endometrial cancer. Cochrane Database Syst Rev. 2023 Mar 27;3(3):CD012513. doi: 10.1002/14651858.CD012513.pub3.
Related trials for Endometrial Cancer
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Active, not recruitingPhase 3
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
Endometrial Cancer
RecruitingPhase 3
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
RecruitingPhase 3
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mary Playdon, PhD, MPH principal investigator
University of Utah
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Time Restricted Eating (TRE) Schedule in people with Endometrial Cancer, run by University of Utah at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 30 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Mary Playdon, PhD, MPH ((801) 213-6264, mary.playdon@hci.utah.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of Women Referred that are Consented (time frame: From baseline to Visit 5 (Week 16)). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04783467, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Nov 2023.